Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Woodcock: FDA maintains NSURE focus; J&J rebrands to regain consumer trust; Symrise AG gains research loan; most allergy sufferers take two or more meds, Teva-funded survey finds; Mead Johnson’s Nutramigen LGG reduces milk allergies; more news In Brief.

You may also be interested in...



J&J OTC Business Returns To Double-Digit U.S. Growth In Q1

The domestic OTC/nutritionals business grew more than 14% in the first quarter on the strength of McNeil products returning to market and a severe cold and flu season. Johnson & Johnson’s consumer performance exceeded some market analyst estimates.

QUOTED. 18 January 2021. Chad Reynolds.

Chad Reynolds of RMQ+ spoke to Medtech Insight about practical strategies for managing economic operators efficiently and with a view to long-term compliance.

Dr Reddy’s Wants To Break Into Top Five In India

Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.

Topics

Related Companies

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel